(+)-Dehydroabietylamine derivatives target triple-negative breast cancer
- 1 September 2015
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 102, 9-13
Abstract
No abstract availableKeywords
Funding Information
- American Lebanese Syrian Associated Charities
This publication has 31 references indexed in Scilit:
- Selective, Nontoxic CB2 Cannabinoid o-Quinone with in Vivo Activity against Triple-Negative Breast CancerJournal of Medicinal Chemistry, 2015
- Targeting a cell state common to triple‐negative breast cancersMolecular Systems Biology, 2015
- Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancerBreast Cancer Research and Treatment, 2014
- Triple-negative breast cancer: investigating potential molecular therapeutic targetExpert Opinion on Therapeutic Targets, 2014
- Targeting triple-negative breast cancer cells with 6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazolesEuropean Journal of Medicinal Chemistry, 2014
- Cancer statistics, 2014CA: A Cancer Journal for Clinicians, 2014
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Emerging targeted therapies in triple-negative breast cancerAnnals of Oncology, 2012
- Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010Journal of Natural Products, 2012
- Triple negative breast cancer cell lines: One tool in the search for better treatment of triple negative breast cancerBreast Disease, 2011